Cartalax – 20mg Spray
Cartalax is a synthetic bioregulator peptide (comprising the sequence Ala-Glu-Asp) studied for its targeted interaction with cartilage and connective tissue. It belongs to the class of short peptides investigated for their ability to bind to DNA and influence the expression of genes responsible for the synthesis of the extracellular matrix. Researchers study Cartalax for its potential to stimulate chondrocyte activity and investigate the biological mechanisms of joint tissue regeneration and structural preservation.
Findings from early-stage clinical trials have reported:
- Enhanced synthesis of collagen and proteoglycans observed in cartilage tissue cultures.
- Improvements in the structural integrity of joint surfaces reported in experimental models.
- Reductions in the frequency of oxidative stress markers within connective tissue noted in-vivo.
- Observed stabilization of the metabolic processes within joint fluid reported in research cohorts.
Researchers utilize Cartalax to explore the epigenetic regulation of cartilage health and the prevention of tissue senescence. By analyzing its impact on protein synthesis in the musculoskeletal system, it serves as a valuable tool for investigating the mitigation of age-related joint decline. Its high degree of tissue specificity makes it a focal point for research into regenerative orthopedics and the preservation of systemic mobility.
Available Formats:
This compound is available in a 9ml premixed spray bottle, providing a stable solution for precise administration in research settings.
Used solely for in vitro experiments and cannot be:
- Used in clinical trials involving humans
- Administered to humans as part of an experiment or investigation
- Supplied to another party for human investigational use
| IDENTIFICATION | |
| Product Name | Cartilax 20 mg |
| Catalogue Number | RP-CARTILAX-01 |
| CAS Number | 87815447 |
| Molecular Weight (g/mol) | Not uniquely defined |
| Molecular Formula | Peptide bioregulator (not uniquely defined) |
| Peptide Sequence | Cartilage-specific regulatory peptide |
| PHYSICAL AND CHEMICAL PROPERTIES | |
| Active Ingredient | Cartilax |
| Appearance | White to off-white lyophilised powder |
| Melting Point | Not applicable (decomposes before melting) |
| ANALYTICAL AND QUALITY CONTROL | |
| Mass Spectrum | Conforms to specification |
| Structural Confirmation | Consistent with theoretical structure / sequence |
| RESEARCH USE AND SAFETY | |
| Caution | Handle using appropriate PPE and in compliance with relevant laboratory safety standards. |
| Intended Use | For laboratory research use only. Not for human or veterinary use. |
| Hazard Classification | Not classified as hazardous under GHS for research quantities |
| STORAGE, HANDLING AND STABILITY | |
| Storage Temperature, Opened | -20 °C, minimise freeze–thaw cycles |
| Storage Temperature, Unopened | -20 °C recommended for long-term storage |
| Shelf Life | 2 years unopened under recommended conditions |
| Reconstitution Stability | Stable for up to 28 days at 2–8 °C in aqueous solution under sterile conditions |
Certificate of Analysis – Cartalax (99% Purity Verified)
| COMPOUND IDENTIFICATION | |
| Product Name | Cartalax (20mg Spray) |
| Batch / Reference ID | CA201111 |
| Sample Form | White powder in glass vial |
| ANALYTICAL RESULTS | |
| Chemical Purity | 99% (Verified) |
| Measured Content | 21.33 mg (± 0.05 mg) |
| Test Method | HPLC (High-Performance Liquid Chromatography) |
| LABORATORY TESTING INFORMATION | |
| Analysis Period | 06 Feb 2026 – 10 Feb 2026 |
| Laboratory Order # | 100012230 |
| QUALITY ASSURANCE | |
| Quality Testing Standards | All River Peptides products undergo batch-level laboratory analysis to verify compound identity and confirm purity levels. Learn more on our Quality Testing & Purity Verification page. |
Related Products
